Skip to main content
. 2023 Mar 28;24(7):6384. doi: 10.3390/ijms24076384

Figure 2.

Figure 2

Mechanism of action of IL-17 inhibitors. Secukinumab and ixekizumab bind to IL-17A and inhibit its interaction with the IL-17 receptor. Bimekizumab binds to Il-17A and IL-17F and inhibits the activation of the IL-17RA/RC complex. Brodalumab binds to IL-17RA and blocks the actions of IL-17A,E,F.